Blurry

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Retrieved on: 
Monday, November 20, 2023
Eye, Human, Plasma kallikrein, Safety, Prevalence, Visual acuity, Retina, Diabetic retinopathy, Month, Patient, CET, DME, Part, Caregiver burden, Brussels Stock Exchange, Blurry, Diabetes, IDMC, Paratriathlon, Bankruptcy, Pharmaceutical industry, Boston

The KALAHARI trial is the only ongoing trial sponsored by Oxurion.

Key Points: 
  • The KALAHARI trial is the only ongoing trial sponsored by Oxurion.
  • The KALAHARI trial evaluated Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for DME patients who respond suboptimally to anti-VEGF therapy.
  • Said Tom Graney, CEO, “We are deeply disappointed that the topline data from the KALAHARI trial did not show improvement in vision from THR-149.
  • I would personally like to thank the incredible team at Oxurion for designing and executing a trial that yielded clearly interpretable results.

Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes

Retrieved on: 
Tuesday, March 14, 2023
CFO, Education, Sarbanes–Oxley Act, Prevalence, Tel Aviv Sourasky Medical Center, IDMC, Month, Plasma kallikrein, System, Eye, Caregiver burden, Macula, Diabetic retinopathy, Human, University, Brussels Stock Exchange, Retina, MBA, CFA, KKS, CET, Diabetes, Part, MD, Patient, Medicare Part D, Inflammation, Tel Aviv University, CST, Safety, Injection, Optical coherence tomography, DME, Blurry, Paratriathlon, Pharmaceutical industry, Medical device, Management, Nursing, Vaccine, Ophthalmology

The KALAHARI trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for patients with diabetic macular edema (DME) who respond suboptimally to anti-VEGF therapy, the current standard of care.

Key Points: 
  • The KALAHARI trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for patients with diabetic macular edema (DME) who respond suboptimally to anti-VEGF therapy, the current standard of care.
  • The Phase 2 KALAHARI trial is a two-part, randomized, prospective, multi-center trial assessing multiple (3) injections of THR-149 in DME patients.
  • Part B is double-masked and actively controlled, with the high dose of THR-149 having been selected from Part A of the trial.
  • The Month 6 data also demonstrated THR-149’s attractive safety profile and its ability to stabilize the Central Subfield Thickness (CST).

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema

Retrieved on: 
Monday, February 27, 2023
Diabetes, Vision, DME, Investigational New Drug, MOA, IND, Diabetic retinopathy, Paratriathlon, FDA, Blurry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, Therapy, Food, Vaccine, Pharmaceutical industry

This regulatory milestone fulfills the Company’s commitment to file the IND for OCU200 within the first quarter of 2023.

Key Points: 
  • This regulatory milestone fulfills the Company’s commitment to file the IND for OCU200 within the first quarter of 2023.
  • DME is one of the most common vision-threatening diseases occurring in people with diabetes and includes blurriness in vision and progressive vision loss as the disease progresses.
  • Approximately 745,000 people in the United States are affected with DME, and this number is expected to further increase as the number of people with diabetes increases.
  • The Company intends to pursue additional indications for OCU200 to potentially treat diabetic retinopathy and wet age-related macular degeneration, which combined affect nearly 9.0 million Americans.

HitPaw Brings The Mac Version of Video Enhancer to Improve the Video Quality

Retrieved on: 
Monday, September 26, 2022
Software, Haze, Portrait, Creativity, MP4, Learning, Noise, MKV, Blurry, Lighting, RMVB, AVI, Artificial intelligence, Animal models of depression, Video-Enhanced Grave Marker, Color, Television, Camera, Video game, Mac

NEW YORK, Sept. 26, 2022 /PRNewswire/ -- HitPaw, a company provides the best digital creation tools, today releases the video enhancement software - HitPaw Video Enhancer Mac .

Key Points: 
  • NEW YORK, Sept. 26, 2022 /PRNewswire/ -- HitPaw, a company provides the best digital creation tools, today releases the video enhancement software - HitPaw Video Enhancer Mac .
  • HitPaw Video Enhancer Mac provides three popular models, including General Denoise Model, Animation Model, and Face Model.
  • HitPaw Video Enhancer Mac is able to provide a clean and bright result by lighting each pixel up in the video using the General Denoise Model.
  • Apart from three AI Model, HitPaw Video Enhancer Mac also supports:
    More than 30 video formats, including MP4, AVI, RMVB, and MKV
    HitPaw Video Enhancer is now compatible with Mac OS 10.15 & above and Windows 11/10(64-bit OS).

Proscia Introduces AI-Powered Quality Control to Accelerate Data-Driven Drug Development

Retrieved on: 
Tuesday, May 17, 2022
Technology, Research, Software, Biotechnology, Health, Pharmaceutical, Data Management, Science, Oncology, Cloud, Digital pathology, Disease, Johns Hopkins School of Medicine, Research, AI, Pathology, Multimedia, Solution, List of life sciences, Automation, Sell Control for Life's Speed, University Medical Center, Melanoma, H&E, COVID-19, Bristol Myers Squibb, University of California, FDA, Efficiency, Pressure, Artifact, University, Technology, Organization, Adoption, Blurry, Charles River Laboratories, Intelligence, University Medical Center Utrecht, Cancer, Diagnosis, Laboratory, Data management, Medical device, Medical imaging, Pharmaceutical industry, Unilab

Proscia , a leader in digital and computational pathology solutions, has introduced an automated quality control application that leverages artificial intelligence to improve quality and efficiency in data-driven drug development.

Key Points: 
  • Proscia , a leader in digital and computational pathology solutions, has introduced an automated quality control application that leverages artificial intelligence to improve quality and efficiency in data-driven drug development.
  • In launching automated quality control, Proscia is delivering on digital pathologys first suite of process automation solutions, streamlining manual, repetitive tasks with AI.
  • View the full release here: https://www.businesswire.com/news/home/20220517005410/en/
    Blurry, unreadable regions of an H&E stained slide image are detected and highlighted with Proscia's AI-powered automated quality control.
  • The launch of automated quality control marks the next milestone in Proscias journey to accelerate the adoption of AI in research and diagnostic pathology.

Puddle Of Mudd Announce New Album, 'Welcome To Galvania'

Retrieved on: 
Friday, July 12, 2019
Songs, Musicians, Puddle of Mudd, She Hates Me, Blurry, Control, Psycho, Wes Scantlin, Wes, Scantlin, Abrasive

It marks the band's first full-length album of new material since 2009'sVolume 4: Songs in the Key of Love and Hate.

Key Points: 
  • It marks the band's first full-length album of new material since 2009'sVolume 4: Songs in the Key of Love and Hate.
  • Having sold over7million albums worldwide and releasing a string of chart-topping hits, including "Blurry," "She Hates Me," "Psycho," and "Control," Puddle of Mudd is finally ready to share some new musicwith their fans.
  • I'm just so happy to finally get it out there for my fans," says Puddle of Mudd's frontman, Wes Scantlin.
  • Welcome toGalvaniaconsists of ten new tracks and was produced by Cameron Webb (Alkaline Trio, Disturbed, Motorhead).